Previous close | 0.6742 |
Open | 0.7200 |
Bid | 0.6808 x 1200 |
Ask | 0.6999 x 1100 |
Day's range | 0.6200 - 0.7200 |
52-week range | 0.6100 - 7.2400 |
Volume | |
Avg. volume | 12,090,823 |
Market cap | 99.277M |
Beta (5Y monthly) | 1.56 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Biotech stocks have taken a beating to start the year, with the S&P Biotech Industry Index down more than 49% so far. There are several reasons a biotech stock could go parabolic -- that is, have its shares see a sharp rise in a short period. The company could be the buyout target of a merger deal with a larger pharmaceutical company.
Strength in Vision Care with the addition of new products and recent acquisition is likely to have contributed to Alcon's (ALC) first-quarter performance.
Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.